Last reviewed · How we verify
Acuvail
At a glance
| Generic name | Acuvail |
|---|---|
| Also known as | Ketorolac 0.45%, anti-inflammatory, ketorolac, topical |
| Sponsor | Vanderbilt University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
- A Phase 1, Double-Blind, Study of the Tolerability of Formulations of Ketorolac Tromethamine Following Intranasal Administration in Healthy Volunteers (Phase 1)
- A Comparison of Peak Aqueous Penetration of Acuvail, Xibrom, and Nevanac in Patients Undergoing Phacoemulsification (Phase 4)
- Comparison of Ketorolac Tromethamine 0.4% and Nepafenac 0.1% for the Prevention of Cystoid Macular Edema After Phacoemulsification: Prospective Randomized Double-masked Study (Phase 4)
- Betamethason Versus Ketorolac Injection for the Treatment of DeQuervains Tenosynovitis (Phase 4)
- The ESCRS EPICAT Study: Effectiveness of Periocular Drug Injection in CATaract Surgery (Phase 3)
- Comparison of Intranasal Desmopressin vs IV Ketorolac in Renal Colic Patients (NA)
- Eptinezumab as an Adjunct to Standard of Care for MIGRANE in an Acute EmeRgency Context (Migraine ERase Study) (Phase 3)
- Analgesic Efficacy of Pre-operative Dose of Ketorolac And Gabapentin in Patients Undergoing Unilateral Total Knee Arthroplasty A Randomized Double Blinded Controlled Trial (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acuvail CI brief — competitive landscape report
- Acuvail updates RSS · CI watch RSS
- Vanderbilt University portfolio CI